Mavyret (AbbVie Inc.)


Welcome to the PulseAid listing for the Mavyret drug offered from AbbVie Inc.. This Hepatitis C Virus NS5A Inhibitor [EPC],P-Glycoprotein Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA],Cytochrome P450 1A2 Inhibitors [MoA],UGT1A1 Inhibitors [MoA],Hepatitis C Virus NS3/4A Protease Inhibitor [EPC],HCV NS3/4A Protease Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA],Cytochrome P450 1A2 Inhibitors [MoA],UGT1A1 Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view the details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.

LABELER NAME / MANUFACTURER: AbbVie Inc.
NON-PROPRIETARY NAME: Glecaprevir and Pibrentasvir
SUBSTANCE NAME: PIBRENTASVIR; GLECAPREVIR
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Hepatitis C Virus NS5A Inhibitor [EPC],P-Glycoprotein Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA],Cytochrome P450 1A2 Inhibitors [MoA],UGT1A1 Inhibitors [MoA],Hepatitis C Virus NS3/4A Protease Inhibitor [EPC],HCV NS3/4A Protease Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA],Cytochrome P450 1A2 Inhibitors [MoA],UGT1A1 Inhibitors [MoA]
ROUTE: ORAL
DOSAGE FORM: TABLET, FILM COATED
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 2017-08-03
END MARKETING DATE: 0000-00-00


Mavyret HUMAN PRESCRIPTION DRUG Details:

Item DescriptionMavyret from AbbVie Inc.
LABELER NAME: AbbVie Inc.
DEA SCHEDULE:
ACTIVE STRENGTH: 40; 100(mg/1; mg/1)
START MARKETING DATE: 2017-08-03
END MARKETING DATE: 0000-00-00
PRODUCT ID: 0074-2625_1028f48b-d19c-7564-6b66-2c7e620367b3
PRODUCT NDC: 0074-2625
APPLICATION NUMBER: NDA209394

Other PIBRENTASVIR; GLECAPREVIR Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
AbbVie Inc.Mavyret